U.S. citizen receives Ketamine therapy

The first U.S. citizen received ketamine-assisted therapy for alcohol use disorder at Nushama clinic in New York.    Awakn Life Sciences developed the "Ketamine for the Reduction of Alcohol Use Disorder" protocol used in the treatment. The protocol combines psychotherapy with ketamine infusions over four weeks. The treatment aims to provide insights into underlying cravings for alcohol and understand behavioral patterns contributing to addiction cycles. A randomized controlled clinical trial of 96 participants demonstrated 86% abstinence from alcohol after six months using the KARE protocol. KARE emphasizes a mindfulness-based psychotherapy component, which includes 18 hours of sessions across four weeks. The ketamine-assisted therapy approach challenges the abstinence-only model traditionally used to treat alcohol use disorder.